Raymond James Financial
CUE icon

Raymond James Financial’s Cue Biopharma CUE Stock Holding History

Raymond James Financial’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-112
Closed -$2.29K – 5364
2025
Q2 		$2.29K Buy
+112
New +$2.39K ﹤0.01% 6379

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's CUE Position: Q3 2025 in Review

Raymond James Financial sold out of Cue Biopharma (CUE) in Q3 2025, closing a stake of 112 shares — an estimated $2.29K sold.

Raymond James Financial first reported a position in CUE in Q2 2025 and held it in 1 quarter. The position peaked at $2.29K in Q2 2025. 51 funds tracked by Wall St. Rank hold CUE as of Q3 2025.

  • Raymond James Financial reported no remaining Cue Biopharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 112 Cue Biopharma shares in Q3 2025, an estimated $2.29K.
  • Raymond James Financial first reported a position in Cue Biopharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Cue Biopharma position peaked at $2.29K in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.